SCYNEXIS (NASDAQ: SCYX) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.
Pfizer pays an annual dividend of $1.28 per share and has a dividend yield of 3.5%. SCYNEXIS does not pay a dividend. Pfizer pays out 36.4% of its earnings in the form of a dividend. SCYNEXIS has increased its dividend for 8 consecutive years.
Earnings & Valuation
This table compares SCYNEXIS and Pfizer’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Pfizer has higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for SCYNEXIS and Pfizer, as reported by MarketBeat.com.
||Strong Buy Ratings
SCYNEXIS presently has a consensus target price of $10.00, suggesting a potential upside of 464.97%. Pfizer has a consensus target price of $39.06, suggesting a potential upside of 6.69%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, research analysts plainly believe SCYNEXIS is more favorable than Pfizer.
This table compares SCYNEXIS and Pfizer’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
SCYNEXIS has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
Insider & Institutional Ownership
31.0% of SCYNEXIS shares are held by institutional investors. Comparatively, 69.9% of Pfizer shares are held by institutional investors. 4.0% of SCYNEXIS shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Pfizer beats SCYNEXIS on 11 of the 17 factors compared between the two stocks.
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.